ILMN Stock Price Today (September 2026) — Illumina, Inc. Analysis & Key Metrics 2026-09-03
Illumina, Inc. (ILMN) is trading at $221.66, up 3.94% today (as of September 2026). The stock continues to show sustained strength above key moving averages, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $198.89 (-10.3% upside).
- Volatility remains elevated (46.27% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (9.40% YoY) alongside significant competitive pressures.
ILMN Stock Analysis: Key Metrics & Valuation (September 2026)
Concise, actionable data for investors
Illumina, Inc. - Historical Price & Volume
Market Cap
Enterprise Value: $33.91B
P/E Ratio
Forward P/E: 35.04
Revenue Growth
Year over Year
Analyst Target
+-10.3% upside potential
Key Investor Questions About ILMN
What investors need to know before buying
Based on current market data, ILMN presents a neutral technical setup with caution warranted fundamentals.
- Technicals say: Neutral (RSI 61.99)
- Fundamentals say: Caution warranted (high leverage concerns)
ILMN's growth trajectory depends on its ability to expand within the Diagnostics & Research sector while managing margin pressures.
- Future growth will depend on performance in core Diagnostics & Research operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for ILMN investors include debt exposure and competitive dynamics in the Diagnostics & Research industry.
- $2.53B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Diagnostics & Research.
52-Week Trading Range
Over the past year, ILMN stock traded between $88.00 and $231.81—recovering meaningfully from lows and currently near the higher end. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 46.27% annualized volatility and β=1.05, the stock exhibits moderate correlation to market moves—making ILMN suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional backing, but elevated short interest signals a potential battleground stock.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
10x Genomics Rallies 84% in 3 Months: Is There More Upside Ahead?
TXG's 84% rally is backed by consumables growth, Atera demand and higher guidance, but weak instruments and valuation raise the bar.
3 High-Flying Stocks We Keep Off Our Radar
Expensive stocks often command premium valuations because the market thinks their business models are exceptional. However, the downside is that high expectations are already baked into their prices, leaving little room for error if they stumble even slightly.
Why Is CRISPR Therapeutics (CRSP) Up 7.1% Since Last Earnings Report?
CRISPR Therapeutics (CRSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
1 Large-Cap Stock with Competitive Advantages and 2 We Find Risky
Large-cap stocks usually command their industries because they have the scale to drive market trends. The flip side though is that their sheer size can limit growth as expanding further becomes an increasingly challenging task.
Should You Add Illumina Stock to Your Portfolio Now?
ILMN's sequencing growth, oncology momentum and multiomics expansion support its outlook, though cost volatility may pressure margins.
Winners And Losers Of Q2: Illumina (NASDAQ:ILMN) Vs The Rest Of The Life Sciences Tools & Services Stocks
Looking back on life sciences tools & services stocks’ Q2 earnings, we examine this quarter’s best and worst performers, including Illumina (NASDAQ:ILMN) and its peers.
Illumina (ILMN) Renews $1b Credit Line After Rally As Fair Value Debate Builds
Illumina (ILMN) has entered a new US$1.0b senior unsecured five year revolving credit facility that replaces its prior agreement, giving the company fresh financing flexibility without any current borrowings reported under the line. Illumina’s new revolving credit facility arrives during a strong run in the stock, with a 7 day share price return of 19.49% and a 90 day share price return of 49.82%. The 1 year total shareholder return of 127.88% contrasts with a 5 year total shareholder return...
Illumina (ILMN) Replaces Prior Deal With $1 Billion Revolving Credit Facility
Illumina (NasdaqGS: ILMN) has entered into a new US$1b unsecured revolving credit facility, replacing its previous agreement. The new facility provides updated covenants and increased flexibility for Illumina's future financing plans. The credit line is expected to serve as a liquidity backstop and support the company's broader capital structure decisions. Consider reviewing other companies with meaningful financing flexibility and balance sheet capacity in related areas through 38 power...
Cancer Vaccine Breakthrough Lifts 5 Biotech Names. Here’s Who’s Best Positioned.
Merck and Moderna just proved their cancer vaccine works, and the ripple effects reach far beyond either company. Five names stand to collect a toll on every single dose manufactured, but not all of them carry the same risk.
What Is Really Moving Tempus AI Stock Right Now?
While traders pointed to external clinical-trial momentum as a major catalyst, Tempus's own recent guidance raise and narrowing losses provided the underlying backdrop.
Explore More Analysis for ILMN
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.
Frequently Asked Questions
Common investor questions about Illumina, Inc.
Illumina, Inc. (ILMN) is currently trading at $221.66. The RSI (14-day) is at 62.0, indicating neutral territory. Wall Street analysts have a consensus "buy" recommendation. The mean analyst price target of $198.89 implies 10.3% downside from current levels. Volatility is high at 46.3% annualized, meaning significant price swings are common. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Illumina, Inc. (ILMN): The trailing P/E ratio is 41.67, which is above the market average, indicating investors are pricing in higher growth expectations. The forward P/E is 35.04, lower than the trailing P/E, suggesting analysts expect earnings improvement. The PEG ratio is 3.23, above 2.0, suggesting the stock may be overvalued relative to its expected growth. Price-to-Book is 11.79. Price-to-Sales is 7.45. Valuation should be compared to Diagnostics & Research industry peers for context, as different sectors trade at different multiples.
Based on 19 analysts covering ILMN, the consensus price target is $198.89. This represents a 10.3% downside from the current price of $221.66. The range spans from a low target of $113.00 to a high target of $230.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Illumina, Inc. (ILMN) does not currently pay a regular dividend. The company may be reinvesting profits into growth initiatives, or may not yet be profitable enough to distribute earnings to shareholders.
Key risks for Illumina, Inc. (ILMN) investors include: 1. High volatility (46.3% annualized)—the stock can experience significant daily price swings. 2. Elevated short interest (10.3% of float) suggests significant bearish sentiment. 3. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 4. Diagnostics & Research sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Illumina, Inc.'s (ILMN) current debt and financial health profile: Total debt stands at $2.53B. The debt-to-equity ratio is 89.04, which is elevated and warrants monitoring, especially in a rising interest rate environment. The current ratio is 1.80, indicating strong short-term liquidity. The quick ratio is 1.25. The company holds $1.17B in cash and equivalents. Free cash flow is positive at $797.63M, providing a cushion for debt servicing and shareholder returns.